You Have Been Invited!
Paula Aguilera, RN
My career in oncology spans many years and includes roles in inpatient oncology, ambulatory oncology, community clinics as well as participation in several committees, with a special interest in improved access to care. I currently work for the Cancer Care Equity Program at Dana Farber Cancer Institute working to address the barriers that prevent patients from getting timely and equitable cancer care.
Innovative Strategies for Second-Line Therapy for SCLC
This curriculum is designed to enhance knowledge, competence, and confidence among oncology clinicians regarding second-line therapy for small cell lung cancer (SCLC). Learners will explore evidence-based treatment sequencing, adverse event management, and emerging clinical trial data to optimize patient outcomes.
Itinerary
Part 1
Please answer the following questions to assess your understanding of second-line therapies for SCLC.
This module covers Small Cell Lung Cancer (SCLC), including its biology, clinical presentation, diagnosis, treatment, and emerging therapies for improved patient outcomes.
This module explores second-line therapies for relapsed or refractory small cell lung cancer (SCLC), reviewing chemotherapy, immunotherapy, and emerging treatments. Key topics include treatment resistance, patient selection, and clinical decision-making through case discussions.
In this module, clinical trial data on emerging agents for SCLC are explored, focusing on novel mechanisms of action, efficacy outcomes, and their potential to improve patient care.
Please answer the following questions to assess your gained understanding of second-line therapies for SCLC.
Participants will review and discuss clinical considerations for sequencing second-line therapies to optimize outcomes for SCLC patients. This session will also address selecting appropriate treatments based on chemotherapy-free intervals and guideline recommendations.
Part 2
Exploring a 70-year-old patient with extensive-stage small cell lung cancer who relapsed four months after treatment, with imaging showing progression and new liver metastases.
In this Group Challenge, you’ll meet MS, a 58-year-old female diagnosed with ES-SCLC, and on three main treatment regimens. We pick up her case at 6 month follow up when CNS complications appear.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the management of your patients with SCLC using 2nd line therapies.
This session will explore strategies for mitigating and managing adverse events associated with second-line therapies in SCLC. Participants will also discuss the mechanisms, administration, and safety profiles of emerging therapeutic agents to enhance patient care.
